Cutler Whitely is a biotech venture builder operating at the intersection of advanced therapeutics, medtech, and commercialization strategy.

​

He currently serves as a Launchpad Commercialization Associate at LifeX and as Commercial Lead for Myosthenos, a translational biotechnology company selected as a finalist in Nucleate New York’s Activator Program. His work focuses on market architecture, capital strategy, technical diligence, and investor-facing execution—building the bridge between lab discovery and scalable enterprise.

​

Cutler’s background spans the full stack of biotech innovation:

• Industry drug discovery at Novartis Institutes for BioMedical Research (NIBR) in early-stage cancer therapeutics

• MedTech venture leadership as Head of R&D and Product Development at Astellar Labs

• Contract research and manufacturing strategy in business development at Apeloa Pharmaceutical Co., Ltd

• Academic research and clinical science at Penn Medicine, Thomas Jefferson University Hospitals, and Drexel University College of Medicine

​

He earned a Master of Science in Biotechnology (4.0 GPA) from Brown University, where his thesis focused on active targeting antifungal drug delivery systems and commercialization strategy. He is currently completing his Executive MBA at Columbia Business School, where he is active in the Aerospace & Defense Club, Venture Capital Club, and Health Care Industry Association.

​

Before biotech, Cutler competed internationally on the World Snowboard Tour—an experience that shaped his approach to risk, discipline, and high-performance execution. Raised in rural Pennsylvania in a blue-collar family, he brings a grounded, operational mindset to frontier technologies.

His focus today is building durable biotechnology platforms that translate complex science into measurable impact—combining technical fluency with capital discipline and commercialization rigor.